CCL2-mediated monocytes regulate immune checkpoint blockade resistance in pancreatic cancer

Int Immunopharmacol. 2022 May:106:108598. doi: 10.1016/j.intimp.2022.108598. Epub 2022 Feb 17.

Abstract

The immunosuppressive microenvironment of pancreatic ductal adenocarcinoma (PDAC) contributes to resistance to immune checkpoint blockade. C-C motif chemokine ligand 2 (CCL2) is believed to participate in pancreatic tumorigenesis, but its role in PDAC progression and resistance to immune checkpoint blockade remains unclear. We hypothesized that CCL2 contributes to the pancreatic immunosuppressive microenvironment. In this study, we found that CCL2 recruits monocytes to and decrease CD8+ T cell infiltration in pancreatic tumors. CCL2 inhibition and monocyte neutralization increased the sensitivity of PDAC to immune checkpoint blockade. The findings of our study suggest the potential of CCL2-mediated monocytes as a target for PDAC treatment.

Keywords: CCL2; Immunosuppression; Immunotherapy; Monocytes; Pancreatic ductal adenocarcinoma.

MeSH terms

  • Chemokine CCL2*
  • Chemokines
  • Drug Resistance, Neoplasm*
  • Humans
  • Immune Checkpoint Inhibitors* / therapeutic use
  • Ligands
  • Monocytes*
  • Pancreatic Neoplasms*
  • Tumor Microenvironment

Substances

  • CCL2 protein, human
  • Chemokine CCL2
  • Chemokines
  • Immune Checkpoint Inhibitors
  • Ligands